Treatment and predictors of outcome in dogs with immune-mediated thrombocytopenia

J Am Vet Med Assoc. 2011 Feb 1;238(3):346-52. doi: 10.2460/javma.238.3.346.

Abstract

Objective: To characterize the clinical course of disease and identify prognostic indicators for immune-mediated thrombocytopenia in dogs.

Design: Retrospective cohort study.

Animals: 73 dogs treated for immune-mediated thrombocytopenia at the Foster Hospital for Small Animals at the Tufts Cummings School of Veterinary Medicine and the Tufts Veterinary Emergency Treatment and Specialties Hospital.

Procedures: Medical records from the period of January 2002 through June 2008 were reviewed to identify dogs with a diagnosis of immune-mediated thrombocytopenia. Data collected included signalment, clinical signs, results of initial diagnostic tests, treatment, complications, and survival duration.

Results: Dog ages ranged from 5 months to 15 years (median, 8.1 years). Cocker Spaniels were overrepresented, compared with their distribution in the entire hospital population during the same period. Sixty-one of the 73 (84%) dogs survived to discharge. Seven (11 %) of those dogs were lost to follow-up. Five of the remaining 54 (9%) dogs had a relapse of the disease. The presence of melena or high BUN concentration at admission to the hospital was significantly correlated with a decreased probability of survival.

Conclusions and clinical relevance: Immune-mediated thrombocytopenia is a serious yet treatable disease, which may have a lower rate of recurrence than previously reported. The presence of melena or high BUN concentration in the study suggested a poor prognosis for affected dogs.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Animals
  • Dog Diseases / drug therapy*
  • Dog Diseases / pathology
  • Dogs
  • Female
  • Gastrointestinal Agents / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy
  • Purpura, Thrombocytopenic, Idiopathic / pathology
  • Purpura, Thrombocytopenic, Idiopathic / veterinary*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Gastrointestinal Agents
  • Immunosuppressive Agents